Along with the rise of the ICI immunotherapy, PD-L1 expression or tumor proportion score (TPS) that serves as a predictive biomarker to identify patients who will likely benefit from immunotherapeutic agents has been recognized. This evidence concerns the gene CD274 and neoplasm.